Last deal

$157M

Amount

Series B

Stage

19.03.2024

Date

3

all rounds

$221M

Total amount

date founded

Financing round

General

About Company
Engrail Therapeutics develops transformative medicines for life-limiting nervous system diseases.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2019

Number of employees

Company Type

For Profit

Last funding type

Series B

IPO status

Private

Description

The company unites biological insights with clinically meaningful solutions to build a diversified portfolio of simplified therapies for complex diseases, reducing the overall disease burden for patients with life-limiting nervous system diseases.
Contacts
Similar Companies
1000
SAGE Therapeutics

SAGE Therapeutics

SAGE Therapeutics is developing medicines to treat rare and orphan diseases of the central nervous system.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Cambridge, MA, USA

total rounds

10

total raised

$2.7B
Cerebral Therapeutics

Cerebral Therapeutics

Cerebral Therapeutics develops combination therapies for refractory epilepsy and neurological diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Health Care, Biotechnology, Therapeutics

Location

Aurora, CO, USA

total rounds

4

total raised

$85.8M
Denali Therapeutics

Denali Therapeutics

Denali Therapeutics develops therapies for neurodegenerative diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

San Francisco, CA, USA

total rounds

6

total raised

$1.12B
Travere Therapeutics

Travere Therapeutics

Travere Therapeutics develops life-changing therapies for rare diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

San Diego, CA, USA

total rounds

7

total raised

$942M

count Of Investments

1

Financials

Funding Rounds
3
3

Number of Funding Rounds

$221M

Money Raised

Their latest funding was raised on 19.03.2024. Their latest investor Abrdn. Their latest round Series B

Date 
Funding Round 
Investors 
Money Raised 
Lead 
F-Prime Capital

F-Prime Capital

F-Prime Capital is a venture capital firm that invests in technology, healthcare and life sciences sectors in the United States and Europe.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Venture Capital, Financial Services, Health Care

Location

Cambridge, MA, USA

count Of Investments

356

count Of Exists

44
Forbion

Forbion

Netherlands-based venture capital firm investing in life sciences and MedTech companies.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Venture Capital, Biotechnology, Financial Services

Location

Naarden, Netherlands

count Of Investments

163

count Of Exists

68
Norwest Venture Partners

Norwest Venture Partners

Norwest is a global venture capital and growth equity investment firm.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Venture Capital, Financial Services, Finance

Location

Palo Alto, CA, USA

count Of Investments

777

count Of Exists

174
Nan Fung Life Sciences

Nan Fung Life Sciences

Nan Fung Life Sciences is a global life sciences investment platform backed by the Nan Fung Group.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Biotechnology, Life Science, Financial Services

Location

San Francisco, CA, USA

count Of Investments

19

count Of Exists

2
Nan Fung Life Sciences

Nan Fung Life Sciences

Nan Fung Life Sciences is a global life sciences investment platform backed by the Nan Fung Group.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Biotechnology, Life Science, Financial Services

Location

San Francisco, CA, USA

count Of Investments

19

count Of Exists

2
Co-Investors
Investors
11
4

Number of lead investors

11

Number of investors

Investor 
Lead 
Round 
Partners 
No
Series B
No
Series B
Abrdn

Abrdn

Abrdn is a UK-based company that offers a full range of capabilities to empower clients in planning, saving and investing for their futures.

Sector

Investment Banking and Brokerage Services

Subsector

Investment Services

Keywords

Financial Services

Location

Edinburgh, UK

total rounds

3

total raised

$5.6M

count Of Investments

15
Longwood Fund

Longwood Fund

Longwood Fund is a venture capital firm that invests in healthcare and life science companies, focusing on biotechnology and therapeutics.

Sector

Closed End Investments

Subsector

Closed End Investments

Location

Boston, MA, USA

count Of Investments

47

count Of Exists

5
Forbion

Forbion

Netherlands-based venture capital firm investing in life sciences and MedTech companies.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Venture Capital, Biotechnology, Financial Services

Location

Naarden, Netherlands

count Of Investments

163

count Of Exists

68
Jasper Bos

Jasper Bos

Jasper Bos, PhD is Director with Merck Serono Ventures, the corporate venture capital fund of Merck Serono SA, which invests in early stage and start-up biotech and pharmaceutical companies. Prior to joining Merck Serono SA, Jasper was instrumental in the founding of IFHA, a private equity fund backed by large Dutch and international institutional investors. He was instrumental in the structuring and capital raise of IFHA and negotiated and managed private equity investments in emerging economies in the healthcare and insurance sectors. Before IFHA, Jasper worked as health economics and strategy manager at the Netherlands Vaccine Institute. Currently, he is a Member of the Board of Directors of Prexton Therapeutics SA, EpiTherapeutics AS, Galecto Biotech, Neviah Genomics and an Observer to the Board of Vaximm AG. He holds a PhD in Pharmacy from the University of Groningen, the Netherlands and has published more than 30 articles on health economics and vaccines.

current job

Forbion
Forbion
Acquisitions
1
Acquiree Name 
Date 
Price 
Acquisition Name 
Neurocycle Therapeutics acquired by Engrail Therapeutics

Neurocycle Therapeutics acquired by Engrail Therapeutics

acquirer

Engrail Therapeutics
Engrail Therapeutics

date

02.02.2021

type

Acquisition
Neurocycle Therapeutics

Neurocycle Therapeutics

Neurocycle Therapeutics is a biopharmaceutical company specializing in sub-type selective GABA-A modulation.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Cambridge, MA, USA

total rounds

1

total raised

$10.57K

People

Founders
2
Stephen Cunningham
Stephen Cunningham

Stephen Cunningham

Dr. Stephen Cunningham is a 25 year pharmaceutical veteran who has led teams that delivered on the development, regulatory approvals and launch of numerous significant products to improve patient health. He has global experience leading cross-functional teams from Phase 1 through life cycle management in the areas of Neuroscience, Cardiovascular, Metabolism, Respiratory, Immunology, Oncology, Women’s Health, Transplant and Clinical Pharmacology. During his career, Stephen lead and developed diverse cross-functional teams in Europe, Japan, Asia, Canada and the United States and has broad and deep experience in setting strategic direction, delivering projects, restructuring organizations and implementing transformational organization change. Stephen started his career at ICI Pharmaceuticals, holding global positions of increasing responsibility at ICI, Zeneca then Novartis. After joining Novartis in 2000 as Head of Medical Affairs in the US, Stephen quickly assumed the role of Chief Scientific Officer and Head of US Clinical Development, Medical Affairs and Evidence-Based Medicine in 2001. While at Novartis he built a world-class Novartis US Clinical Development and Medical Affairs organization supporting drug development, launch and life cycle management of products worldwide. Since 2014, Stephen has worked with venture capital, as a strategic consultant and as an independent board director.

current job

Engrail Therapeutics
Engrail Therapeutics

organization founded

1

Stephen Cunningham

Vikram Sudarsan
Vikram Sudarsan

Vikram Sudarsan

Vikram Sudarsan is Strategy Head of Cipla New Ventures at Cipla USA since October 2013. Vikram is a versatile biotech pharma professional with deep expertise in the scientific and commercial aspects of drug development. Prior to joining Cipla, Vikram helped start IMS's new Transaction Advisory Practice – IMS Health Capital, Inc. as an Engagement Manager in Partnership. Prior to that Vikram helped establish and grow the Asset Valuation practice at PriceSpective, LLC before its sale to ICON Plc. At IMS and PriceSpective he built a differentiated risk-sharing based licensing, mergers & acquisitions business. Vikram led global teams to develop a deep understanding of assets value and potential before advising clients on transactions. Vikram has led due diligence projects for several of the top twenty pharma companies on the buy-side and strategy development projects for numerous small biotech clients on the sell-side. Vikram is an INLAKS scholar. Vikram has a Ph.D. in Genetics from University of Sheffield, UK and carried out his doctoral research at the University of Cambridge. Vikram has a Post Doctorate in Neurobiology from Stanford University Howard Hughes Medical Institute. Vikram has an M.Sc. degree in Biochemistry from MS University Baroda.

current job

Engrail Therapeutics
Engrail Therapeutics

Vikram Sudarsan

Employee Profiles
2
Vikram Sudarsan

Vikram Sudarsan

Co-Founder , President & CEO

Stephen Cunningham

Stephen Cunningham

Co-Founder ,Executive VP & Chief Development Officer

Activity

Recent News
4
News Timeline

The graph reveals the ratio (%) of positive news articles in a chosen time range

month